Nantong Jinghua Pharmaceutical Co Ltd

Jinghua Pharmaceutical Group Co., Ltd. is a China-based company that researches, develops, produces, and sells pharmaceuticals domestically and internationally. Its product portfolio includes active pharmaceutical ingredients (APIs) and intermediates, chemical and pharmaceutical intermediates, Chinese medicinal herbs and materials, health products, and Western medicine products. The company also offers branded medicines such as Jidesheng antivenomous tablets, Nantong Wang's baby health pill, Ningning ZhengChaihu granules, Dachaihu granules, Gubenkechuan tablets, dizziness treatment syrup, and Jinqiaomai tablets, as well as APIs including phenobarbital, primidone, fluorouracil, phenylbutazone, flucytosine, piroxicam, tenoxicam, and propylthiouracil. In addition, it engages in enterprise management, technical services, import and export of goods and technology, chemical wholesale, pharmaceutical retail, medical device equipment sales, cosmetics and skincare products, and investment activities. Formerly known as Nantong Jinghua Pharmaceutical Co., Ltd., the company was founded in 1957 and is headquartered in Nantong, China.

002349.CS▲5

Jinghua Pharmaceutical's 2026 interim net profit reaches 136 million yuan, up 4.20% year-on-year

Jinghua Pharmaceutical released its 2026 interim report, with total operating revenue of 755 million yuan, up 3.19% year-on-year, and net profit attributable to the parent of 136 million yuan, up 4.20% year-on-year. Net cash inflow from operating activities was 111 million yuan, the asset-liability ratio was 10.68%, gross margin was 54.26%, ROE was 4.81%, and diluted earnings per share was 0.17 yuan. The number of shareholders was 76,500, and the top ten shareholders held 40.02% of the total share capital.

002349.CS ▲

Jiemian·23dRead more →

002349.CS

Jinghua Pharmaceutical CFO Cheng Jian resigns, Zhao Li takes over

Jinghua Pharmaceutical announced that Chief Financial Officer Cheng Jian has resigned due to a job reassignment, but will remain as a director and general manager. Cheng Jian holds 770,000 shares in the company, and the resignation will not affect normal operations. The board has approved the appointment of Zhao Li as the new CFO, with a term starting from the date of this board resolution until the end of the sixth board's term. In the first quarter of 2026, Jinghua Pharmaceutical reported revenue of 380 million yuan and net profit attributable to the parent of 65.87 million yuan.

002349.CS

财中社·57dRead more →